序贯疗法治疗幽门螺旋杆菌(HP)感染性胃溃疡的临床疗效及其安全性

Clinical Efficacy and Safety of Sequential Therapy in the Treatment of Helicobacter Pylori(HP) Infection Gastric Ulcer

目的:评价序贯疗法治疗幽门螺旋杆菌(Helicobacter pylori,HP)感染性胃溃疡的临床疗效,并分析该疗法的安全性。方法:选择88例HP感染性胃溃疡患者,患者为2016年4月—2017年4月到我院消化内科就诊,按双色球随机抽取法将患者分为每组各44人的对照组和治疗组,对照组患者接受三联疗法,治疗组患者接受序贯疗法,对两组患者的疗效进行评价,同时分析安全性。结果:治疗组与对照组总有效率比较(95.45%vs 79.55%),有显著的统计学差异(P<0.05);治疗组与对照组不良反应发生率比较(6.82%vs 20.45%),有显著的统计学差异(P<0.05)。结论:序贯疗法治疗幽门螺旋杆菌感染性胃溃疡疗效确切,不良反应小,安全性高。

Objective To evaluate the clinical efficacy of sequential therapy in the treatment of Helicobacter pylori （HP） infection gastric ulcer and toanalyze the safety of the treatment. Methods： 88 patients with HP infected gastric ulcer were selected. The patient was admitted to our departmentof gastroenterology from April 2016 to April 2017. The patients were divided into 44 control group and treatment group according to the randomextraction method of double chromospheres. Patients in the control group received triple therapy. The patients in the treatment group receivedsequential therapy. The curative effect and security of the two groups was evaluated. Results： Compared with the control group, the total effectiverate of treatment group （95.45%vs79.55%）, there was significant difference （P〈0.05）;The treatment group compared with the control group adversereaction rate （6.82%vs20.45%）. There is a statistically significant difference （P〈0.05）. Conclusion： Sequential therapy is effective and safe in thetreatment of Helicobacter pylori infection gastric ulcer with little adverse reaction and high safety.